Compare GYGY & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYGY | EVAX |
|---|---|---|
| Founded | 2 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 27.5M |
| IPO Year | 2026 | 2020 |
| Metric | GYGY | EVAX |
|---|---|---|
| Price | $0.45 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 3.4M | 35.7K |
| Earning Date | 11-20-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $2.77 |
| 52 Week High | $11.81 | $12.15 |
| Indicator | GYGY | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 15.04 | 39.88 |
| Support Level | N/A | $2.92 |
| Resistance Level | $1.27 | $3.62 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 1.25 | 0.00 |
Game Your Game Inc develops and markets AI-based sports performance tracking technology that is prominently focused on the golf industry. Its products include GPS shot tracking hardware, AI algorithms, and a smart coaching app to provide players with real-time insights, recommendations, and personalized performance analytics. The company's technology consists of the GameGolf KZN AI platform, which is an integrated golf performance ecosystem of proprietary shot-tracking hardware and subscription-based software solutions. It generates revenue from the sale of KZN AI hardware device and from recurring annual subscription fees for continued access to the GameGolf App, GameGolf Smart Caddie and the GameGolf platform. Geographically, the company operates mainly in the United States and Europe.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.